Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option and Sells Shares Under 10b5-1 Plan

Enliven Therapeutics' CFO, Benjamin Hohl, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 28, 2024, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to purchase 6,250 shares of common stock at a price of $2.48 per share.
• Hohl then sold 5,600 shares at a weighted average price of $28.4933 and 650 shares at a weighted average price of $29.111.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns 0 shares of common stock and 173,806 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction under a pre-arranged plan, so it doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of shares by the CFO could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• There are no specific risks mentioned in this document.

Industry Context

This type of filing is standard for corporate insiders and is a regular occurrence in the biotech industry.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among corporate executives to diversify their holdings and avoid accusations of insider trading.
• The filing is consistent with SEC regulations regarding insider trading and transparency.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, but the pre-planned nature of the sales mitigates potential concerns.

Key Dates